Published in Nephrol Dial Transplant on December 02, 2013
Polymeric drugs: Advances in the development of pharmacologically active polymers. J Control Release (2015) 0.81
Contemporary management of phosphorus retention in chronic kidney disease: a review. Clin Exp Nephrol (2015) 0.76
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2009) 12.66
Uric acid and cardiovascular risk. N Engl J Med (2008) 12.20
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int (2002) 9.29
Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med (2000) 8.47
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis (1998) 7.79
Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int (2006) 6.61
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol (2004) 6.50
Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2006) 5.69
Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med (2009) 4.05
Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant (2000) 3.99
Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol (2002) 3.83
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int (2005) 3.71
Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int (2005) 3.56
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int (2007) 3.34
Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol (2008) 3.26
Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis (2000) 2.65
K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis (2003) 2.62
The emerging role of phosphate in vascular calcification. Kidney Int (2009) 2.14
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis (2010) 1.93
Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis (2012) 1.91
J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis (2006) 1.88
Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int (2012) 1.86
Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol (2008) 1.46
Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol (2012) 1.38
Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis (2010) 1.29
Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol (2012) 1.27
Uric acid as a target of therapy in CKD. Am J Kidney Dis (2012) 1.22
Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev (2011) 1.05
Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol (2008) 1.02
Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. Nephrology (Carlton) (2011) 1.00
Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis (2011) 1.00
Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol (2007) 0.98
Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles. Am J Kidney Dis (2010) 0.85
Association of HbA1c values with mortality and cardiovascular events in diabetic dialysis patients. The INVOR study and review of the literature. PLoS One (2011) 0.84
Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. Drugs (2008) 0.84
Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era. J Nephrol (2012) 0.82
Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects. Nephron Clin Pract (2012) 0.81
Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant (1996) 0.78
Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant (2009) 0.78
Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant (2005) 0.77
Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrol Dial Transplant (2013) 0.77
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Genetic loci influencing kidney function and chronic kidney disease. Nat Genet (2010) 3.75
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet (2003) 3.70
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
EBPG on Vascular Access. Nephrol Dial Transplant (2007) 3.26
EBPG guideline on nutrition. Nephrol Dial Transplant (2007) 2.68
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant (2010) 2.64
Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab (2008) 2.60
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab (2007) 2.51
Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 2.51
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int (2008) 2.36
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation (2003) 2.22
Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab (2010) 2.13
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant (2003) 2.10
Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation (2009) 2.07
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl (2003) 2.04
Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis (2011) 2.01
EBPG guideline on dialysis strategies. Nephrol Dial Transplant (2007) 1.90
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med (2006) 1.87
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr (2013) 1.85
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J (2010) 1.72
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol (2006) 1.71
Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet (2012) 1.69
Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. PLoS Genet (2011) 1.68
EBPG guideline on haemodynamic instability. Nephrol Dial Transplant (2007) 1.65
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol (2008) 1.52
Effects of lowering dialysate calcium concentration on mineral metabolism and parathyroid hormone secretion: a multicentric study. Ther Apher Dial (2007) 1.47
Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant (2008) 1.46
Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus. Atherosclerosis (2009) 1.45
Can we decrease organ trafficking in the Balkans? Clin Transplant (2011) 1.44
Tei index in fabry disease. J Am Soc Echocardiogr (2011) 1.44
OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant (2011) 1.44
Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis (2005) 1.43
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol (2006) 1.43
Endothelial progenitor cells in patients on extracorporeal maintenance dialysis therapy. Nephrol Dial Transplant (2010) 1.41
Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta (2010) 1.35
Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail (2009) 1.35
Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int (2002) 1.33
The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J (2005) 1.32
Understanding competing risks: a simulation point of view. BMC Med Res Methodol (2011) 1.31
Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int (2013) 1.31
Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. FASEB J (2003) 1.31
Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol (2011) 1.29
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27
Factors influencing the decision to start renal replacement therapy: results of a survey among European nephrologists. Am J Kidney Dis (2012) 1.26
Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol (2006) 1.25
Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med (2013) 1.25
Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation (2005) 1.24
Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tract. Clin J Am Soc Nephrol (2012) 1.24
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol (2011) 1.23
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol (2013) 1.23
Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe. Nephrol Dial Transplant (2011) 1.23
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant (2011) 1.23
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant (2009) 1.22
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol (2011) 1.19
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol (2008) 1.19
Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation (2013) 1.13
Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol (2011) 1.13
Advanced glycation end products and mortality in hemodialysis patients. Kidney Int (2002) 1.12
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol (2014) 1.12
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant (2010) 1.11
Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med (2014) 1.11
Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation (2009) 1.10
The 2008 ERA-EDTA Registry Annual Report-a précis. NDT Plus (2010) 1.10
The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant (2011) 1.09
A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol (2014) 1.08
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol (2007) 1.07
20 years since the establishment of the BANTAO association (Balkan Cities Association of Nephrology, Dialysis, Transplantation and Artificial Organs). Prilozi (2013) 1.07
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant (2013) 1.07
Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol (2014) 1.07
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin J Am Soc Nephrol (2009) 1.06
Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int (2003) 1.06
Novel insights into uremic vascular calcification: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. Blood Purif (2002) 1.06
Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J (2008) 1.05
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int (2010) 1.04
Homoarginine, cardiovascular risk, and mortality. Circulation (2010) 1.04
Statins, inflammation and kidney disease. Nat Rev Nephrol (2011) 1.04
The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant (2009) 1.04
Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int (2009) 1.03
Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet (2014) 1.03
Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis (2007) 1.02
Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog. J Pharmacol Exp Ther (2005) 1.01
Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. Kidney Int Suppl (2003) 1.01
Down-regulation of MTUS1 in human colon tumors. Oncol Rep (2010) 1.01
Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging (2011) 1.00
Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant (2005) 1.00
Implementation of proteomic biomarkers: making it work. Eur J Clin Invest (2012) 1.00
Sample sizes for clinical trials with time-to-event endpoints and competing risks. Contemp Clin Trials (2005) 0.98
Geriatric nephrology is coming of age. J Am Soc Nephrol (2003) 0.98
Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int (2008) 0.98
The issue of studying the effect of interventions in renal replacement therapy -- to what extent may we be deceived by selection and competing risk? Nephrol Dial Transplant (2010) 0.97
Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant (2003) 0.97